Document registry — page 16
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its…
Moderate18 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low17 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High16 May 2026 -
Randomised, double-blind, active-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over 72 weeks. The Institute holds no reported primary…
14 May 2026 -
For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and what can be…
Very low13 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low13 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Dulaglutide maintained across the full duration of the contributing trials?
High12 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor…
Moderate10 May 2026 -
In the population defined for obesity and overweight in adults, is the effect of Survodutide maintained across the full duration of the contributing trials?
Moderate10 May 2026 -
Bacterial endotoxin determination in peptide preparations intended for parenteral use
High10 May 2026 -
Randomised crossover, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low10 May 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low08 May 2026 -
In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
High07 May 2026 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with…
Moderate07 May 2026 -
Octapeptide tight-junction regulator (zonulin antagonist). Larazotide antagonises zonulin-mediated tight-junction disassembly, reducing paracellular permeability in intestinal epithelium. The therapeutic…
Moderate07 May 2026 -
Research peptides with a worldwide warehouse network. Founded 2017.
07 May 2026 -
Endogenous tripeptide thiol antioxidant. Glutathione is the dominant intracellular low-molecular-weight thiol and the cofactor of the glutathione peroxidase and S-transferase systems…
Low06 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate05 May 2026 -
Peptides with a global warehouse network. Trades as GGPeps.
05 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low05 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the…
Moderate02 May 2026 -
Oral non-peptide GLP-1 receptor partial agonist. Orforglipron activates the GLP-1 receptor from a non-peptide scaffold, producing the insulinotropic, glucagonostatic and central appetite effects of…
Moderate30 Apr 2026 -
Pharmacological modification of innate or adaptive immune function, assessed by cell counts, functional assays and clinical infection or oncological endpoints.
27 Apr 2026 -
37-residue cationic antimicrobial host-defence peptide. LL-37 permeabilises bacterial membranes through an amphipathic helical mechanism and separately acts as a chemoattractant and immunomodulator through…
Low27 Apr 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its…
High26 Apr 2026 -
A pattern of alcohol use characterised by impaired control, salience, and physiological features, meeting recognised diagnostic criteria.
26 Apr 2026 -
Consultation on the draft synthesis of incretin receptor agonists in adolescents. The contributing evidence is small, drawn principally from the adolescent arm of the…
24 Apr 2026 -
Consultation on the draft monograph for 5-amino-1MQ, which the assessment committee released for public comment before ratification. The draft grades the compound's…
23 Apr 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate21 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor…
High20 Apr 2026 -
Synthetic ACTH(4-10) analogue heptapeptide. Semax is reported to increase expression of brain-derived neurotrophic factor and its receptor TrkB in rodent hippocampus, and to modulate…
Low19 Apr 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Low17 Apr 2026 -
GLP-1 receptor agonist (exendin-based, short- and extended-release). Exenatide is a naturally DPP-4-resistant GLP-1 receptor agonist. The immediate-release presentation gives short, high peaks that produce a pronounced…
High17 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Apr 2026 -
In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High15 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor…
High14 Apr 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High14 Apr 2026 -
Consultation on the second version of the synthesis of glucagon-like peptide-1 receptor agonists for weight reduction in adults with obesity. The revision re-runs the…
13 Apr 2026 -
Consultation on the draft of CEI-MS-19, which specifies the performance a determination must achieve for chromatographic purity and states what the resulting figure does…
13 Apr 2026 -
Obesity arising from structural hypothalamic injury or a defined genetic syndrome affecting the melanocortin pathway or energy homeostasis.
11 Apr 2026
page 16 of 41